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Coxiella burnetii is an obligate intracellular bacterium. The inability to cultivate this organism on axenic
medium has made calculation of infectious units challenging and prevents the use of conventional antibiotic
susceptibility assays. A rapid and reliable real-time PCR assay was developed to quantify C. burnetii cells from
J774.16 mouse macrophage cells and was applied to antibiotic susceptibility testing of C. burnetii Nine Mile,
phase I. For calculation of bacterial replication, real-time PCR performed equally as well as immunofluores-
cent-antibody (IFA) assay when J774.16 cells were infected with 10-fold serial dilutions of C. burnetii and was
significantly (P < 0.05) more repeatable than IFA when 2-fold dilutions were used. Newly infected murine
macrophage-like J774.16 cells were treated with 8 g of chloramphenicol per ml, 4 g of tetracycline per ml,
4 g of rifampin per ml, 4 g of ampicillin per ml, or 1 g of ciprofloxacin per ml. After 6 days of treatment,
tetracycline, rifampin, and ampicillin significantly (P < 0.01) inhibited the replication of C. burnetii, while
chloramphenicol and ciprofloxacin did not. In general, these results are consistent with those from prior
reports on the efficacy of these antibiotics against C. burnetii Nine Mile, phase I, and indicate that a real-time
PCR-based assay is an appropriate alternative to the present methodology for evaluation of the antibiotic
susceptibilities of C. burnetii.
Coxiella burnetii, the etiologic agent of Q fever, is an obligate
intracellular bacterium. C. burnetii is widely distributed in na-
ture and infects a variety of mammals, birds, reptiles, fish, and
ticks (19). In humans, infection is usually the result of inhala-
tion of contaminated aerosols associated with infected sheep,
goats, and, to a lesser extent, cattle. The prevalence of C. bur-
netii infections has been difficult to determine, in part, due to
the lack of surveillance. One recent retrospective study indi-
cated that seropositivity rates in Japan were greater than 20%
in at-risk individuals (7). Q fever may manifest as either an
acute or chronic illness (13). Acute disease commonly presents
as a self-limiting influenza-like illness accompanied by fever
and severe headaches, and the prognosis is usually favorable
(16). Recovery from acute infections usually occurs within 1 to
2 weeks and can be accelerated with antibiotics such as tetra-
cyclines. However, diagnosis of acute infections often occurs
too late for tetracyclines to be effective, and misdiagnoses can
lead to inappropriate treatment or a lack of treatment alto-
gether (10, 24). Chronic disease can be life threatening and
most often presents as endocarditis or hepatitis (13). Even with
antimicrobial intervention, mortality rates have been reported
to be as high as 24% (2). The most effective treatment of
chronic Q fever includes a combination of doxycycline and
chloroquine administered for at least 18 months (13). In cases
of tetracycline intolerance or contraindication, alternative and
often less effective antibiotics are used (13). The pursuit of
new and more effective treatments for Q fever remains an
area of active research. Two recent studies based on in vitro
sensitivities indicated that certain macrolides and trovafloxacin
were good potential candidates for the treatment of Q fever (5,
6).
One of the challenges investigators face when determining
C. burnetii antibiotic sensitivities is calculating bacterial num-
bers. In many intracellular bacterial infection models, infec-
tious units can be measured by plating lysates on semisolid
media for CFU determination or performing an agar overlay
for PFU determination. However, C. burnetii has yet to be
cultivated on axenic medium, and a plaquing system (23) has
been difficult to adapt to most laboratories. Thus, the inability
to cultivate this bacterium on axenic medium prevents the use
of conventional assays to test antibiotic susceptibilities. There-
fore, three different systems have been used to evaluate the
antibiotic susceptibilities of C. burnetii, including an animal
model (8), an embryonated egg model (9), and several cell
culture models (26). These methods are time-consuming and
difficult to use for testing of multiple antibiotics with multiple
clinical isolates. In order to overcome this limitation, a shell
vial assay was developed that used immunofluorescent-anti-
body (IFA) assay to determine the bacteriostatic and bacteri-
cidal activities of antibiotics (17). The disadvantages of this
technique are that it is labor-intensive and results must be
determined by blinded scoring because of the subjectivity of
the test. Therefore, techniques based at the molecular level
have the potential to be more efficient methods for determi-
nation of the antimicrobial susceptibilities of C. burnetii.
In this report, we describe the application of a SYBR Green
I dye-based real-time PCR assay to antibiotic susceptibility
testing of C. burnetii. This assay provides a rapid and sensitive
method for determination of C. burnetii antibiotic sensitivi-
ties and eliminates the subjectivity associated with other meth-
ods.
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MATERIALS AND METHODS
Oligonucleotide primers. Primers FAF216 (5-GCACTATTTTTAGCCGG
AACCTT-3) and RAF290 (5-TTGAGGAGAAAAACTGGATTGAGA-3),
which amplify a 74-bp fragment of the C. burnetii com1 gene (GenBank accession
no. AF318146), which is highly conserved among 21 C. burnetii strains (27), were
selected by using Primer Express software (PE Applied Biosystems, Foster City,
Calif.). The primers were synthesized by the Gene Technologies Laboratory at
Texas A&M University, College Station.
Preparation of standard curve. To construct a standard curve, total genomic
DNA was purified from C. burnetii Nine Mile, phase I (RSA 493), which is
considered the representative strain for acute infections (10, 18). The DNA
concentration was measured spectrophotometrically and converted to genome
copy numbers by using the molecular weight of DNA. Briefly, the weight of one
C. burnetii genome copy (in grams) was calculated by multiplying the size of the
C. burnetii genome (2.1 106 bp) by the average mass of a DNA base pair (615
Da) (20) and then multiplying this number by the weight of 1 atomic mass unit
(1.67  1024 g) (22). This number was then divided into the concentration of
the total genomic DNA to determine how many genome copies were in each
microliter of the genomic DNA. Tenfold serial dilutions ranging from 107 to 101
genome copies were then made.
PCR assay conditions. Real-time PCR was performed with an ABI Prism 7700
sequence detector (PE Applied Biosystems) according to the empirical design of
the manufacturer. Briefly, template DNA was added to a reaction mixture con-
taining 0.3 M each primer, 12.5 l of 2 SYBR Green I PCR Master Mix (PE
Applied Biosystems), and 8 l of distilled H2O in a final volume of 25 l. All
reactions were carried out in 96-well plates. After initial activation of AmpliTaq
Gold DNA polymerase at 95°C for 10 min, 40 PCR cycles of 95°C for 15 s and
60°C for 1 min were performed. Cycle threshold (Ct) values were determined by
using cycles 3 to 9 as the baseline. Assay specificity was confirmed by subjecting
the PCR products to agarose gel electrophoresis and SYBR Green I melting
FIG. 1. Establishment of the standard curve for C. burnetii quantification. (A) Amplification plots of C. burnetii standards. Genome concen-
trations are (from left to right) 107, 106, 105, 104, 103, 102, and 101. For each dilution the normalized fluorescence signal (Rn) is plotted against
the PCR cycle number. (B) Standard curve generated from the Ct values of the amplification plots with ABI Sequence Detection software. This
curve represents the standard curve only; no unknowns are represented in this graph.
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curve analysis by using three separate holds of 95°C for 15 s, 60°C for 20 s, and
95°C for 15 s, with a ramp time of 19 min and 59 s from the second to the third
holding temperatures.
Extraction of C. burnetii DNA from infected tissue culture cells. C. burnetii
DNA was extracted from murine macrophage-like J774.16 cells by resuspending
cell pellets in 200 l of lysis buffer (6.25 ml of 2 M Tris [pH 7.5], 1 ml of 0.5 M
EDTA, 50 mg of glucose, and 200 mg of lysozyme brought to a final volume of
50 ml with distilled H2O) plus 10 l of 20 mg of proteinase K per ml for 4 h at
60°C. Following this treatment, 21 l of 10% sodium dodecyl sulfate was added,
and the mixture was incubated for 1 h at room temperature. DNA was recovered
by using the High Pure PCR template preparation kit (Roche Molecular Bio-
chemicals, Indianapolis, Ind.).
Comparison of real-time PCR to IFA. J774.16 mouse macrophages were
plated at a concentration of 105 cells/ml in 24-well tissue culture plates (Becton
Dickinson, Franklin Lakes, N.J.) with or without coverslips and incubated for 4 h
at 37°C in 5% CO2 for attachment. The cells were then inoculated with either 10-
or 2-fold serial dilutions of C. burnetii Nine Mile, phase I (RSA 493), and
incubated overnight at 37°C in 5% CO2. Samples for real-time PCR were pre-
pared as described above.
Immunofluorescence antibody staining (IFA) was performed on samples
plated into wells containing coverslips. The wells were washed three times with
warm Dulbecco modified Eagle medium with L-glutamine and supplemented
with 10% fetal bovine serum (DMEM; Fisher Scientific, Houston, Tex.), fixed
with 2% paraformaldehyde–100% methanol–1% toluene, and washed once with
phosphate-buffered saline (PBS). Five hundred microliters of rabbit anti-C. bur-
netii Nine Mile antiserum diluted 1:300 in PBS–2% normal goat serum was
added, and the mixture was incubated at room temperature for 1 h, followed by
three 5-min washes in PBS. Five hundred microliters of Alexa Fluor 488 goat
anti-rabbit immunoglobulin G (heavy and light chains; Molecular Probes, Eu-
gene, Oreg.) diluted 1:300 in PBS–2% normal goat serum was added, and the
mixture was incubated at room temperature for 1 h. Coverslips were washed
three times for 5 min each time in PBS, mounted on slides, and examined by
fluorescence microscopy. The IFA result was expressed as an infection index,
which is the product of the mean number of bacteria per infected cell and the
percentage of infected cells multiplied by 100 (3).
Antibiotic susceptibility testing. J774.16 mouse macrophages were plated at a
concentration of 105 cells/ml in 24-well tissue culture plates and incubated for 4 h
at 37°C in 5% CO2 to allow attachment. The medium was removed, and the
monolayers were inoculated with C. burnetii Nine Mile, phase I (RSA 493),
diluted 1:500 in DMEM, and incubated overnight. Infected cells were washed
FIG. 2. Determination of PCR specificity. (A) Melting curve analysis performed with ABI Dissociation Curve software revealed that the
com1-specific primer pair amplified a single predominant product with a melting temperature of 81.3°C. (B) Agarose gel electrophoresis of the
amplified product with ethidium bromide staining shows the presence of a single band, confirming the specificity of the PCR assay. Lane 1, 100-bp
molecular mass marker; lane 2, amplified product from a C. burnetii DNA standard dilution of 107; lane 3, blank; lane 4, amplified product from
a 1:200 dilution of the C. burnetii inoculum.
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three times with warm DMEM to remove noninternalized bacteria and were
then treated with antibiotics or sham treated. The concentrations of each of the
antibiotics used were as follows: chloramphenicol, 8 g/ml; tetracycline, 4 g/ml;
rifampin, 4 g/ml; ampicillin, 4 g/ml; and ciprofloxacin, 1 g/ml. These con-
centrations are the lower critical concentrations according to the French Anti-
biogram Committee (1) and were previously reported to have bacteriostatic
effects against C. burnetii (17, 21). Fresh medium with antibiotics was added on
days 1, 2, 3, 4, 5, and 6 postinoculation. Sham-treated cells received DMEM only
and served as a reference to create growth curves for treated samples. Samples
for real-time PCR were collected on days 1, 2, 4, and 7 postinoculation.
Statistical analysis. Significant differences between methods and between
antibiotic treatment groups were assessed by the paired Student t test. The
repeatability of each method (i.e., the variability of a method when repeated
measures are taken within a single experiment) was estimated by computing the
percent coefficient of variation (CV; the ratio between the standard deviation
and the mean of the repeated measurements multiplied by 100).
RESULTS
Prior to application of the real-time methodology to antimi-
crobial sensitivity testing of C. burnetii, several steps were
taken to validate the assay. First, a BLAST search of the
ENTREZ database indicated that oligonucleotide primers
FAF216 and RAF290 were specific for com1. Tenfold serial
dilutions of purified C. burnetii genomic DNA were used to
construct a standard curve, from 107 copies at the start to 101
copies. Figure 1A presents typical amplification plots for these
standards. A standard curve was then generated from the Cts
of the amplification plots with ABI Sequence Detection soft-
ware (Fig. 1B). The slope of the standard curve was 3.297,
indicating that the efficiency of the PCR was approximately
100%, according to the equation E 101/s 1, where E is the
run efficiency and s is the slope of the standard curve (4).
Melting curve analysis revealed that the primer pair ampli-
fied a single predominant product with a distinct melting tem-
perature, indicating that fluorescence from misprimed prod-
ucts or primer dimers would not hinder C. burnetii quantitation
(Fig. 2A). Specificity was confirmed by agarose gel electro-
phoresis, which demonstrated the presence of a single ampli-
con of approximately 100 bp (Fig. 2B). The primers designed
with Primer Express software were predicted to amplify a
74-bp product. This discrepancy between the predicted size
and the size of the band seen in the gel is likely due to a
decrease in the mobility of the fragment as a result of bound
SYBR Green I dye and the limits of resolution of agarose gel
electrophoresis.
The precision of the assay was determined by measuring Ct
values for eight replicates of the standards (Table 1). The
results represent independent dilution series and different
PCR runs. The mean Ct, standard deviation, and percent CV
were calculated for each template concentration. The results
showed low variability, with CVs ranging from 1.2 to 5.6%,
indicating that the assay was efficiently reproducible.
To further validate the assay, tissue culture cells were inoc-
ulated with either 10- or 2-fold dilution series of C. burnetii,
incubated overnight, and quantified by both IFA and real-time
PCR. When 10-fold dilutions from 1:100 to 1:100,000 were
used, both IFA and real-time PCR results showed strong linear
relationships (r  0.99) (Fig. 3A). The repeatability of each
assay was determined by calculating the percent CV at each
dilution. The CVs ranged from 7.1 to 33% and from 10.3 to
55% for the real-time PCR and IFA, respectively (Table 2).
These results show that the repeatabilities of the real-time
PCR and IFA were similar at dilutions of 1:100 and 1:1,000,
but as the number of infectious organisms decreased, the CV
of IFA was considerably greater. The CVs for the real-time
PCR at 1:10,000 and 1:100,000 dilutions of the inoculum were
12.5 and 33%, respectively, whereas for IFA they were 44 and
53%, respectively. At twofold dilutions of the inoculum from
1:200 to 1:1,600, the linearities of both assays were again sim-
ilar (r 0.84) (Fig. 3B). CVs ranged from 3.6 to 13% and from
8.8 to 26% for the real-time PCR and IFA, respectively (Table
2). Again, as the number of infectious organisms decreased,
the repeatability of IFA was not as consistent as that of the
real-time PCR assay. The CVs for the real-time PCR at 1:800
and 1:1,600 dilutions of the inoculum were 13 and 3.6%, re-
FIG. 3. Validation of real-time PCR by comparison to IFA. The
results are represented as the means and standard errors of three
replicates. (A) Tenfold dilution series; (B) twofold dilution series.
Circles, real-time PCR data; diamonds, IFA data.
TABLE 1. Summary of eight different PCR runs performed
on eight separate dilution series
Concn (no. of copies/l) Mean Ct SDa CV (%)
107 10.68 0.35 3.3
106 13.52 0.16 1.2
105 17.08 0.21 1.2
104 20.82 0.61 2.9
103 24.72 1.39 5.6
102 28.92 1.63 5.6
101 31.61 0.84 2.7
a SD, standard deviation of eight replicates.
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spectively, whereas for IFA they were 26 and 25%, respec-
tively.
Real-time PCR was used to evaluate the effectiveness of
antibiotics previously shown to be bacteriostatic for C. burnetii
Nine Mile, phase I, by the shell vial assay. Newly infected
J774.16 cells were treated for 6 days with 8 g of chloram-
phenicol per ml, 4 g of tetracycline per ml, 4 g of rifampin
per ml, 4 g of ampicillin per ml, or 1 g of per ciprofloxacin
ml, which are the lower critical bacteriostatic concentrations
(1). Total DNA was extracted and antibiotic efficacies were
determined. Sham-treated infected cells served as positive con-
trols for C. burnetii replication. For each treatment or control
group, J774.16 cell viabilities were greater than 90%. The re-
sults of C. burnetii antibiotic susceptibility testing are shown in
Fig. 4. After 6 days of treatment, tetracycline, rifampin, and
ampicillin significantly inhibited the replication of the bacteria
(P 	 0.01) while chloramphenicol and ciprofloxacin did not
inhibit replication compared to the results for the sham-
treated controls. Of the bacteriostatic antibiotics, rifampin was
the most effective, followed by tetracycline and ampicillin.
DISCUSSION
The results of this study demonstrate that a real-time PCR
assay can be used for the rapid and reliable determination of
C. burnetii antimicrobial susceptibilities without the subjectiv-
ity associated with microscopic enumeration methodologies.
The use of com1 as a target gene allowed the specific ampli-
fication of C. burnetii DNA over a 7-log DNA concentration
range. The specificity of the assay was confirmed by a search
for primer-specific sequences with the BLAST program, melt-
ing curve analysis, and agarose gel electrophoresis of the PCR-
amplified products. Comparison of the real-time PCR and IFA
revealed that the real-time PCR assay was more repeatable.
No statistically significant difference (P 
 0.05) was found
between the percent CVs obtained by the real-time PCR assay
and those obtained by the IFA method when 10-fold dilutions
were used. However, when twofold dilutions were used, the
real-time PCR assay did perform significantly better (P 	
0.05). With the 10- and 2-fold dilution series of the C. burnetii
inoculum, the real-time assay consistently detected more bac-
FIG. 4. Effects of chloramphenicol, tetracycline, rifampin, ampicillin, and ciprofloxacin on C. burnetii replication in J774.16 cells. Antibiotic-
treated cells were assayed on day 7. Sham-treated cells were assayed on days 1, 2, 4, and 7 postinoculation and served as a control for bacterial
replication. Open bar, day 1; black bar, day 2; stippled bar, day 4; striped bars, day 7. Results are reported as the means and standard errors for
three replicates.
TABLE 2. CVs of 10- and 2-fold dilutions of C. burnetii inoculum
quantified by real-time PCR and IFA
Dilution
CV (%)
Real-time PCR IFA
10-fold
1:100 10.7 10.8
1:1,000 7.1 10.3
1:10,000 12.5 44.0
1:100,000 33.0 53.0
2-fold
1:200 6.0 8.8
1:400 11.0 18.0
1:800 13.0 26.0
1:1,600 3.6 25.0
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teria at each dilution, suggesting that this assay is more sensi-
tive. This finding may be attributed in part to the inherent
difficulty of accurately counting the number of bacteria in a
three-dimensional cell when only one dimension is accessible.
Thus, the traditional immunofluorescence staining method
(IFA) may ultimately result in underestimation of the number
of intracellular bacteria.
Due to the acidic nature of the intracellular environment in
which C. burnetii resides, it has been difficult but critical to find
drugs effective for the treatment of Q fever, especially chronic
manifestations of infection. Several studies have been done to
evaluate the effectiveness of a wide range of antibiotics against
C. burnetii (11, 12, 15, 17). However, the shell vial assay used in
those studies to determine the effectiveness of a specific anti-
biotic requires at least 6 days to determine the effect of anti-
biotic treatment on replication rates. The real-time PCR based
assay described here provides an alternative method that can
be used to rapidly evaluate the effectiveness of antibiotics
against C. burnetii. Results can be obtained within 24 h after
the completion of drug treatments. Our results indicate that
C. burnetii Nine Mile, phase I, was susceptible to tetracycline
and rifampin at concentrations of 4 g/ml, which is in accor-
dance with the results of a previous study (17). Our results also
indicate that this strain was not susceptible to chloramphenicol
at a concentration of 8 g/ml or to ciprofloxacin at a concen-
tration of 1 g/ml, which is not in complete agreement with the
results of the previous study (17). Previous work demon-
strated that the efficacies of chloramphenicol and ciprofloxacin
against C. burnetii varied (14, 17, 25, 26), depending on the
dose, the culture model, and the C. burnetii strain used to test
the antimicrobials. The ability of ampicillin to inhibit C. bur-
netii growth supports prior evidence presented by Suhan et al.
(21) that C. burnetii Nine Mile, phase I, is susceptible to am-
picillin at 50 g/ml. At present, the recommended treatments
for C. burnetii infections involve doxycycline for 2 weeks for
acute infections and doxycycline plus chloroquine for at least
18 months for chronic infections. There are, however, several
drawbacks to these treatments. Neither of these regimens has
been proven to be bactericidal in vitro, and no reliable treat-
ment is available for children and pregnant women (13).
Therefore, it is important to continue to evaluate alternative
treatments for Q fever. We propose that a real-time PCR-
based approach to rapid screening of multiple antibiotic can-
didates is an appropriate alternative to the present methodol-
ogy.
In conclusion, the real-time PCR assay described in this
study provides a rapid and reliable way to quantify C. burnetii
infectious units in tissue culture models. This assay offers sev-
eral advantages over traditional staining techniques, including
the elimination of subjectivity, reduced labor, and the ability to
standardize reporting of results. In addition to studies that are
screening potential antimicrobial agents, studies that use this
assay to evaluate bactericidal host responses against C. burnetii
are in progress.
ACKNOWLEDGMENTS
This work was supported by Public Health Service grants AI37744
and AI448191 from the National Institute of Allergy and Infectious
Diseases.
We thank Laurie Davidson for technical assistance and Jon Skare,
Vernon Tesh, and Rene´e Tsolis for critical review of the manuscript.
REFERENCES
1. Acar, J., E. Bergogne-Berezin, Y. Chabbert, R. Cluzel, A. Courtieu, P. Cour-
valin, H. Dabernat, H. Drugeon, J. Duval, J. P. Flandrois, J. Fleurette, F.
Goldstein, M. Meyran, C. Morel, A. Philippon, J. Sirot, C. J. Soussy, A.
Thabaut, and M. Verus. 1990. Communique du comitte de l’antibiogramme.
Pathol. Biol. 38:749–752.
2. Brouqui, P., H. T. Dupont, M. Drancourt, Y. Berland, J. Etienne, C. Leport,
F. Goldstein, P. Massip, M. Micoud, A. Bertrand, et al. 1993. Chronic Q
fever: ninety-two cases from France, including 27 cases without endocarditis.
Arch. Intern. Med. 153:642–648.
3. Dellacasagrande, J., C. Capo, D. Raoult, and J.-L. Mege. 1999. IFN--
mediated control of Coxiella burnetii survival in monocytes: the role of cell
apoptosis and TNF. J. Immunol. 176:2259–2265.
4. Fink, L., W. Seeger, L. Ermert, J. Hanze, U. Stahl, F. Grimminger, W.
Kummer, and R. M. Bohle. 1998. Real-time quantitative RT-PCR after
laser-assisted cell picking. Nat. Med. 4:1329–1333.
5. Gikas, A., D. P. Kofteridis, A. Manios, J. Pediaditis, and Y. Tselentis. 2001.
Newer macrolides as empiric treatment for acute Q fever infection. Antimi-
crob. Agents Chemother. 45:3644–3646.
6. Gikas, A., I. Spyridaki, A. Psaroulaki, D. Kofterithis, and Y. Tselentis. 2001.
In vitro susceptibility of Coxiella burnetii to trovafloxacin in comparison with
susceptibilities to pefloxacin, ciprofloxacin, ofloxacin, doxycycline, and clar-
ithromycin. Antimicrob. Agents Chemother. 42:2747–2748.
7. Htwe, K. K., T. Yoshida, S. Hayashi, T. Miyake, K.-I. Amano, C. Morita, T.
Yamaguchi, H. Fukushi, and K. Hirai. 1993. Prevalence of antibodies to
Coxiella burnetii in Japan. J. Clin. Microbiol. 31:722–723.
8. Huebner, R. J., G. A. Hottle, and E. B. Robinson. 1948. Action of strepto-
mycin in experimental infection with Q fever. Public Health Rep. 63:357–
362.
9. Jackson, E. R. 1951. Comparative efficacy of several antibiotics on experi-
mental rickettsial infections in embryonnated eggs. Antibiot. Chemother.
1:231–235.
10. Marrie, T. J., and D. Raoult. 1997. Q fever—a review and issues for the next
century. Int. J. Antimicrob. Agents 8:145–161.
11. Maurin, M., A. M. Benoliel, P. Bongrand, and D. Raoult. 1992. Phagolyso-
somal alkalinization and the bactricidal effect of antibiotics: the Coxiella
burnetii paradigm. J. Infect. Dis. 166:1097–1102.
12. Maurin, M., and D. Raoult. 1997. Bacteriostatic and bactericidal activity of
levofloxacin against Rickettsia rickettsii, Rickettsia conorii, ‘Israeli spotted
fever group rickettsia’ and Coxiella burnetii. J. Antimicrob. Chemother. 39:
725–730.
13. Maurin, M. R., and D. Raoult. 1999. Q fever. Clin. Microbiol. Rev. 12:518–
553.
14. Ormsbee, R. A., H. Parker, and E. G. Pickens. 1955. The comparative
effectiveness of aureomycin, terramycin, chloramphenicol, erythromycin, and
thiocymetin in suppressing experimental rickettsial infections in chick em-
bryos. J. Infect. Dis. 96:162–167.
15. Raoult, D., M. Drancourt, and G. Vestris. 1990. Bactericidal effect of doxy-
cycline associated with lysosomotropic agents on Coxiella burnetii in P388D1
cells. Antimicrob. Agents Chemother. 34:1512–1514.
16. Raoult, D., and T. Marrie. 1995. Q fever. Clin. Infect. Dis. 20:489–496.
17. Raoult, D., H. Torres, and M. Drancourt. 1991. Shell-vial assay: evaluation
of a new technique for determining antibiotic susceptibility, tested in 13
isolates of Coxiella burnetii. Antimicrob. Agents Chemother. 35:2070–2077.
18. Samuel, J. E., M. E. Frazier, and L. P. Mallavia. 1985. Correlation of
plasmid type and disease caused by Coxiella burnetii. Infect. Immun. 49:775–
779.
19. Sawyers, L. A., D. B. Fishbein, and J. E. McDade. 1987. Q fever: current
concepts. Rev. Infect. Dis. 9:935–946.
20. Stewart, R. D. 1997. Ph.D. dissertation. Kansas State University, Manhattan.
21. Suhan, M. L., C. Shu-Yin, and H. A. Thompson. 1996. Transformation of
Coxiella burnetii to ampicillin resistance. J. Bacteriol. 178:2701–2708.
22. Whitten, K. W., R. E. Davis, and M. L. Peck. 1996. General chemistry.
Harcourt Brace College Publishing, New York, N.Y.
23. Wike, D. A., G. Tallent, M. G. Peacock, and R. A. Ormsbee. 1972. Studies of
the rickettsial plaque assay technique. Infect. Immun. 5:715–722.
24. Yeaman, M. R., and O. G. Baca. 1990. Antibiotic susceptibility of Coxiella
burnetii, p. 213–223. In T. J. Marrie (ed.), Q fever. The disease, vol. 1. CRC
Press, Boca Raton, Fla.
25. Yeaman, M. R., M. J. Roman, and O. G. Baca. 1989. Antibiotic susceptibil-
ities of two Coxiella burnetii isolates implicated in distinct clinical syndromes.
Antimicrob. Agents Chemother. 33:1052–1057.
26. Yeaman, M. R., L. A. Mitscher, and O. G. Baca. 1987. In vitro susceptibility
of Coxiella burnetii to antibiotics, including several quinolones. Antimicrob.
Agents Chemother. 31:1079–1084.
27. Zhang, G. Q., H. To, T. Yamaguchi, H. Fukushi, and K. Hirai. 1997. Dif-
ferentiation of Coxiella burnetii by sequence analysis of the gene (com1)
encoding a 27-kDa outer membrane protein. Microbiol. Immunol. 41:871–
877.
1874 BRENNAN AND SAMUEL J. CLIN. MICROBIOL.
 o
n
 Septem
ber 12, 2018 by guest
http://jcm.asm.org/
D
ow
nloaded from
 
